Surveillance primarily involves imaging, most commonly by ultrasound with or without alpha-fetoprotein (AFP) every 6 months, as recommended by the recent guidelines from the American Association for the Study of Liver Diseases (AASLD) [2, 4]. This evidence concerns the gene AFP and liver disorder.